A heritage Psilocybe cubensis lineage descended from collections in the Ecuadorian Andean foothills; noted for cold-tolerance and reliably moderate flushes.
§ 01Morphology
Ecuador produces mid-sized fruits with cinnamon-to-tan caps of 30–70 mm at maturity. The stipe is visibly thicker and less prone to elongation than is typical for lowland P. cubensis — a trait commonly attributed to the variety's descent from Andean foothill material.
Bruising is a standard blue-green, and gills mature through the characteristic species progression from pale grey to deep purple-black. Fruiting bodies display modest variability in cap shape between flushes; individual specimens are dense rather than expansive.
§ 02Origin & Naming
The Ecuador designation refers to spore collections drawn from the Andean foothills of western Ecuador, with community sources placing initial distribution in hobbyist circles through the 1980s. No single founding cultivator or formal academic description is associated with the variety.
Secondary isolations — occasionally distributed under labels such as Ecuadorian or Andean Ecuador — are best understood as parallel regional stocks of the same population rather than distinct genetic lines.
§ 03Cultivation Temperament
Ecuador tolerates a broader fruiting-temperature range than most P. cubensis varieties, with successful flushes documented as low as 17 °C. Colonisation speed is deliberate rather than rapid; cultivators should expect longer pre-pinning timelines than with Golden Teacher or B+.
Yields are reliable but modest; flushes are seldom spectacular, but the variety is prized for the consistency and reproducibility of its results across environmental conditions.
§ 04Safety Profile
As with all psilocybin-containing species, Ecuador carries significant contraindications. Psilocybin is a serotonergic compound and interacts with a range of medications and mental-health conditions.
⚠ Contraindications
Not suitable for individuals with personal or family history of psychotic disorders, schizophrenia, or bipolar I; those taking SSRIs, MAOIs, or lithium; pregnant or breastfeeding persons; or those with unmanaged cardiovascular conditions. Always review the full safety codex before use.